Biosafety Consulting

A big area of concern for biotech companies is adherence to guidelines concerning the use of recombinant DNA. Many staff members of biotech companies may have come from other backgrounds and may not be familiar with the byzanthine regulations governing the engineering and manipulation of recombinant DNA molecules.

I am Chairman of the Meridian Biosciences/Life Sciences Institutional Biosafety Committee and I am also a member of the Cincinnati Children’s Medical Center Institutional Biosafety Committee. I provide consulting and advisory services in the area of recombinant DNA safety regulation.

Biosafety Issues

The National Institutes of Health (NIH) sets forth detailed procedures for the containment and design of various forms of recombinant DNA research that may be conducted in laboratories receiving funding from the NIH. Even research projects not directly funded by NIH grants and contracts must be reviewed by the IBC in order to provide local review and oversight. All research projects must be approved by the committee.

Childrens Hospital Medical Center is on the forefront of investigation in a number of critical areas, including gene transfer experiments for the treatment of severe genetic disorders.

  • Biosafety Consulting

    Morrow discusses biosafety issues with Dr. Han Van Der Loo, Director of the Translational Core Facility at Cincinnati Childrens Hospital. The hospital is one of the world's outstanding pediatric research facilities.


    Morrow discussing studies in T cell immunology with Dr. Kasper Hoebe, research scientist at Children's Hospital Medical Center.

About Us

Newport Biotechnology Consultants, founded in 2005, originally was aimed at providing writing expertise in the life sciences industry, with a specialization in molecular immunology. I drew upon my academic and industrial background to cover new developments and technologies in antibody therapies and related areas of biotechnology. These reviews were published in a number of trade journals, especially articles in Genetic Engineering and Biotechnology News (see articles). More recently I have expanded my writing into other fields, including emergency management, drug discovery, bioprocessing, environmental and sustainable technologies, micro- and nanotechnology and many other areas. I also am involved in regulatory issues. I am Chair of the Meridian Bioscience Institutional Biosafety Committee, and I am a member of the Cincinnati Children’s Medical Center Institutional Biosafety Committee (see consulting services). Both IBCs review research protocols dealing with the use of recombinant DNA. Finally, I have consulted for a number of companies on laboratory design, business plan evaluation and regulatory questions.

Recent Posts

Videos, Slideshows and Podcasts by Cincopa Wordpress Plugin